Key result
Early inhibition of myocardial fibrosis in diabetic cardiomyopathy may prevent or delay HF.
Why the study?
Myocardial fibrosis is the main factor causing ventricular wall stiffness and heart failure in diabetic cardiomyopathy, making early control significant to prevent or postpone progression.
This review highlights the critical role of myocardial fibrosis in diabetic cardiomyopathy and summarizes the molecular mechanisms driving its progression.
Caution against routine fibrosis inhibition in diabetic cardiomyopathy; leaves open prospective trials to confirm benefit.
Diabetic cardiomyopathy (DCM), a main cardiovascular complication of diabetes mellitus, can eventually develop into heart failure and seriously affect the prognosis of diabetic patients. Myocardial fibrosis (MF) is the main factor causing ventricular wall stiffness and heart failure in DCM. Early control of MF in DCM is of great significance to prevent or postpone the progression of DCM to heart failure. In this review, we systematically analyzed the relevant studies on diabetic MF in recent years, explored the formation mechanism of MF in the pathological process of DCM, and summarized and analyzed in detail the current studies with antifibrotic treatment for DCM, so as to provide guidance for the development of prevention and treatment strategies for MF in DCM.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) conducted a review in Diabetic cardiomyopathy. Antifibrotic treatments was evaluated. Myocardial fibrosis is a major pathological mechanism of diabetic cardiomyopathy, and early inhibition of its progression through various molecular pathways and pharmacological agents may prevent or delay the development of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: